Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
MWN-AI** Summary
Ovid Therapeutics Inc. has announced the appointment of Dr. Petra Kaufmann as Chief Medical Officer, effective December 2, 2025. In her new role, Dr. Kaufmann will oversee Ovid's clinical, medical, and regulatory strategies, as the company advances its innovative pipeline of treatments for neurological disorders characterized by significant unmet medical needs.
With a vast background in developing central nervous system (CNS) therapeutics, Dr. Kaufmann has experience spanning first-in-human studies to global regulatory approval. Her career began as a neurologist focusing on refractory epilepsy and neuromuscular disorders, providing her with a unique perspective on drug development that prioritizes patient-centric trial design. Prior to joining Ovid, she held leadership roles at Vigil Neuroscience, Affinia Therapeutics, and Novartis Gene Therapies, where she contributed to the global approval of Zolgensma®, the first gene therapy for spinal muscular atrophy.
Dr. Kaufmann's expertise in biomarker strategy and clinical planning is anticipated to bolster Ovid's development efforts for its promising compounds, including the next-generation GABA-AT inhibitor OV329 and novel KCC2 activators. Meg Alexander, Ovid's President and COO, expressed confidence in Dr. Kaufmann's ability to accelerate the development of the company’s distinct programs and enhance its research and development capabilities.
In her statements, Dr. Kaufmann emphasized her long-standing commitment to advancing therapies for complex brain conditions and expressed enthusiasm for the opportunity to contribute to Ovid's mission of delivering patient-focused, scientifically grounded treatments. Her extensive qualifications include an M.D. from the University of Bonn, a Master’s in Biostatistics from Columbia University, and training in neurology and clinical neurophysiology, solidifying her role as a key asset to Ovid Therapeutics' future endeavors.
MWN-AI** Analysis
The recent appointment of Dr. Petra Kaufmann as Chief Medical Officer at Ovid Therapeutics (Nasdaq: OVID) marks a significant strategic shift for the company and may represent an attractive investment opportunity for discerning market participants. With a wealth of experience in developing central nervous system (CNS) therapeutics, Dr. Kaufmann's expertise can bolster Ovid’s pipeline, particularly in areas of high unmet medical need.
Ovid’s focus on developing small molecule medicines aimed at addressing neuronal imbalance through innovative candidates like OV329 and a library of KCC2 direct activators positions it as a key player in the CNS therapeutics space—an area that has long been starved for effective treatments. Dr. Kaufmann's background includes successful leadership roles at companies like Vigil Neuroscience and Affinia Therapeutics, along with pivotal contributions to Zolgensma, the pioneering gene therapy for spinal muscular atrophy. This breadth of experience suggests that she can effectively guide Ovid’s research and development efforts towards successful clinical outcomes and regulatory approvals.
Investors should closely monitor Ovid's progress under Dr. Kaufmann’s leadership, particularly the advancement of OV329 as a potential therapy for treatment-resistant seizures. Given the rising prevalence of neurological disorders and the urgent need for innovative therapies, successful clinical trials could significantly enhance Ovid’s market positioning and elevate share prices.
As Ovid enhances its focus on patient-centric development, those looking to invest should consider the long-term potential of the company, especially in light of increasing healthcare demands for effective CNS treatments. With a strong clinical pipeline and experienced leadership, Ovid Therapeutics is well-poised to capitalize on growth opportunities in the biopharmaceutical sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid’s leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance.
Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives began from her early career as a practicing neurologist who treated patients with refractory and treatment-resistant epilepsies and neuromuscular disorders. She has held leadership roles in biopharmaceutical companies and at the National Institutes of Health, where she directed national rare-disease research and clinical-trial infrastructure. Her background includes patient-focused trial design informed by cutting-edge biomarker strategies and quantitative clinical planning. She is a proven drug developer who will help guide the advancement of Ovid’s next-generation GABA-AT inhibitor, OV329, and the Company’s broad portfolio of first-in-class KCC2 direct activators.
“Petra brings a compelling combination of creative drug development, regulatory experience and the deep care of a physician who has treated people suffering from complex neurological conditions,” sad Meg Alexander, President and Chief Operating Officer of Ovid Therapeutics. “Her appointment strengthens our R&D organization, and we believe her expertise is well suited for translating and accelerating the development of our highly differentiated pipeline programs. The team and I look forward to working alongside Petra as we advance our mission to bring new classes of better, gentler medicines for patients and families who need them.”
“I have dedicated my career to advancing therapies for people living with serious conditions of the brain, including seizures,” said Dr. Kaufmann. “What drew me to Ovid is its commitment to patient-focused development, grounded in rigorous science and differentiated mechanisms. I’m excited to join at this pivotal moment and look forward to working closely with Meg and the Ovid team to thoughtfully advance OV329 and our broader KCC2 portfolio, ensuring each program is guided by sound clinical principles and a deep understanding of patient needs.”
Dr. Kaufmann joins Ovid from Vigil Neuroscience (acquired by Sanofi), where she served as Chief Medical Officer and oversaw the company’s medical, clinical, biomarker, patient advocacy and regulatory functions. Prior to Vigil, Dr. Kaufmann served as Chief Medical Officer of Affinia Therapeutics and as Senior Vice President, Clinical Development, Translational Medicine & Analytics of Novartis Gene Therapies, where she played a key leadership role in the development and global approvals of Zolgensma ® , the first gene therapy for spinal muscular atrophy. Previously, Dr. Kaufmann held senior roles at AveXis (acquired by Novartis) and served as Head of the Office of Rare Diseases Research at the National Institutes of Health (NIH), where she helped advance national research and clinical-trial infrastructure for rare and genetic conditions. While at the NIH, Dr. Kaufmann also served as a part-time reviewer for the Food and Drug Administration’s Division of Neurology Products. Dr. Kaufmann earned her M.D. from the University of Bonn, an M.S. in Biostatistics from Columbia University, and completed specialized training in epileptology and electroencephalography at the University of Bonn. Dr. Kaufmann trained in neurology and clinical neurophysiology at Columbia University Medical Center, where she later served as a tenured faculty member in the Department of Neurology. Dr. Kaufmann is a Fellow of the American Academy of Neurology.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. Ovid is advancing a pipeline of novel targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; and OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Contact
Investor Relations & Media
Victoria Fort
VFort@ovidrx.com
202.361.0445
FAQ**
How does Ovid Therapeutics Inc. OVID plan to leverage Dr. Petra Kaufmann's expertise to enhance its clinical, medical, and regulatory strategies for the development of OV329 and its KCC2 portfolio?
What specific challenges does Ovid Therapeutics Inc. OVID anticipate in advancing its next-generation GABA-AT inhibitor, OV329, given the complexities of developing CNS therapeutics?
With Dr. Kaufmann's appointment, what changes or innovations can investors expect in Ovid Therapeutics Inc. OVID's patient-focused trial design and biomarker strategies?
How does Ovid Therapeutics Inc. OVID intend to address the significant unmet needs in treatment-resistant seizures and other CNS disorders through its pipeline of small molecule candidates?
**MWN-AI FAQ is based on asking OpenAI questions about Ovid Therapeutics Inc. (NASDAQ: OVID).
NASDAQ: OVID
OVID Trading
8.29% G/L:
$1.895 Last:
1,307,794 Volume:
$1.80 Open:
